綠葉製藥(02186.HK)向ESTEVE授予阿爾茨海默病新藥利斯的明多日透皮貼劑在西班牙的商業化權利
9月8日,綠葉製藥集團宣佈,旗下子公司綠葉製藥(瑞士)與Esteve Pharmaceuticals, S.A.(ESTEVE)達成協議,授予後者利斯的明多日透皮貼劑在西班牙的獨家商業化權利。利斯的明多日透皮貼劑用於治療與阿爾茨海默病相關的輕、中度痴呆症,是綠葉製藥自主研發的創新制劑。
合作方ESTEVE成立於1929年,是一家總部位於巴塞羅那的國際製藥公司,在歐洲和美國均有重要業務。綠葉製藥集團董事會相信,ESTEVE作為一家在中樞神經治療領域擁有豐富經驗和強大商業運營體系的知名製藥公司,將擴大利斯的明多日透皮貼劑的可及性,以滿足該地區患者未滿足的需求。
近年來,隨着患者數量的日益攀升,阿爾茨海默病已成為全球範圍的一大公共健康挑戰。該疾病領域的新藥開發挑戰重重,利斯的明是目前治療阿爾茨海默病相關痴呆症的一線用藥,在全球市場銷售。
利斯的明多日透皮貼劑通過創新的給藥途徑,每週經皮膚給藥兩次。與市售的利斯的明單日透皮貼劑相比,利斯的明多日透皮貼劑具有更低的使用頻率,可改善患者的用藥依從性;與口服制劑相比,該藥物通過穿透皮膚被人體吸收,亦為存在吞嚥困難的病患提供了良好的用藥便捷性,並有望降低噁心、嘔吐等腸胃不良反應的發生率。
利斯的明多日透皮貼劑是綠葉製藥在中樞神經治療領域的核心產品,由其專有的透皮釋藥技術平台自主開發,擁有多項國際專利。除了歐洲市場以外,該產品也即將在日本開始III期臨牀試驗,並在中國獲批進入臨牀。綠葉製藥還將在全球其他國家和地區註冊該產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.